|
| View:
Latest News | Top Stories |
|
| 1.
|
Full Approval for J&J's Intelence
-
Zacks.com
-
Tue 4:14 pm ET
J&J's Intelence received full approval from the US Food and Drug Administration for the treatment of HIV patients who are no longer responding to other treatments.
|
|
| 2.
|
Lilly Releases Latest 'Value of Medicine' Resource Guide About Key Issues Facing the Pharmaceutical Industry
-
PR Newswire
-
Tue 3:45 pm ET
The educational resource, "The Value of Medicine, Improving Health... Improving Life," created by Lilly USA , is now available at www.lillyforbetterhealth.com/value_of_medicine.jsp.
|
|
| 3.
|
Analyst Note: Goldman cautious on Abbott, Lilly
-
AP
-
Tue 10:09 am ET
A Goldman Sachs analyst reaffirmed her outlook for Abbott Laboratories and Eli Lilly & Co., but expressed more caution on her respective ratings, citing a mix of drug sales and operating performances in the coming year.
|
|
| 4.
|
Former Johnson & Johnson exec charged in Britain
-
AP
-
Tue 9:13 am ET
A former executive of a Johnson & Johnson subsidiary was on Tuesday charged with conspiracy to corrupt in connection with payments to Greek medical professionals, the Serious Fraud Office said.
|
|
| 5.
|
Spectrum Pharmaceuticals Announces ZEVALINŽ Data Presentations at the 51st Annual Meeting of the American Society of Hematology in New Orleans
-
Business Wire
-
Tue 7:00 am ET
IRVINE, Calif.----Spectrum Pharmaceuticals, Inc. , a commercial stage biotechnology company with a primary focus in oncology, today announced that clinical data on ZEVALIN will be presented at the 51st Annual Meeting of the American Society of Hematology , being held December 5-8, 2009 at the Ernest N.
|
|
| 6.
|
Indianapolis likely losing ATP event after decades
-
AP
-
Mon 5:04 pm ET
Organizers of the Indianapolis Tennis Championships are planning to sell the sanctioning rights for the ATP event, meaning the city may be without a professional tournament for the first time in more than 80 years.
|
|
| 7.
|
Health Care Company Acquisition Price By Private Equity 22% Over Predicted Price By Small Cap Expert
-
Wall Street Transcript
-
Mon 1:41 pm ET
67 WALL STREET, New York - November 26, 2009 - The Wall Street Transcript has just published its TWST Investing Strategies Report offering a timely review of the sector to serious investors and industry executives. This 55 page feature contains expert industry commentary through in-depth interviews with highly experienced Portfolio Managers. The full issue is available via The Wall Street Transcript Online.
|
|
| 8.
|
Increase In Patent Protection For Biologics Creates Significant Upside For Drug Development Enterprise Valuations
-
Wall Street Transcript
-
Sat Nov 28
67 WALL STREET, New York - November 28, 2009 - The Wall Street Transcript has recently published its Q4 2009 Biotechnology Report offering a timely review of the sector to serious investors and industry executives. This 70 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.
|
|
| 9.
|
Big Pharma Mergers: Good News Or Bad?
-
Investor's Business Daily
-
Fri Nov 20
Whoever says you can't throw money at problems hasn't spent much time following the Big Pharma sector this year.
|
|
| 10.
|
Piper Jaffray Award Winning Analyst Says Health Care Reform Equity Valuation Fears Have Passed: Stock Picks For Q4 2009
-
Wall Street Transcript
-
Tue Nov 10
67 WALL STREET, New York - November 10, 2009 - The Wall Street Transcript has just published its Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This 76 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.
|
|
